Venus Remedies Limited (VENUSREM.NS)
INR 305.85
(2.5%)
INR 305.85
(2.5%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.91 Billion INR | -41.18% |
| 2022 | 1.96 Billion INR | 14.42% |
| 2021 | 1.71 Billion INR | -3.28% |
| 2020 | 1.77 Billion INR | 24.3% |
| 2019 | 1.42 Billion INR | 13.05% |
| 2018 | 1.26 Billion INR | -15.57% |
| 2017 | 1.49 Billion INR | 21.44% |
| 2016 | 1.23 Billion INR | -4.08% |
| 2015 | 1.28 Billion INR | -10.1% |
| 2014 | 1.42 Billion INR | 7.2% |
| 2013 | 1.33 Billion INR | 19.55% |
| 2012 | 1.11 Billion INR | 5.67% |
| 2011 | 1.05 Billion INR | 35.81% |
| 2010 | 777.45 Million INR | 26.16% |
| 2009 | 616.24 Million INR | 41.78% |
| 2008 | 434.65 Million INR | 34.8% |
| 2007 | 322.44 Million INR | 58.48% |
| 2006 | 203.46 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 215.1 Million INR | -40.15% |
| 2024 Q2 | 332.4 Million INR | 54.53% |
| 2023 Q2 | 588.5 Million INR | 32.66% |
| 2023 Q3 | 248.4 Million INR | -57.79% |
| 2023 Q4 | 359.4 Million INR | 44.69% |
| 2023 FY | 1.15 Billion INR | -41.18% |
| 2023 Q1 | 443.6 Million INR | -15.26% |
| 2022 Q3 | 456.9 Million INR | -5.56% |
| 2022 Q2 | 483.8 Million INR | -3.63% |
| 2022 Q1 | 502 Million INR | 39.64% |
| 2022 FY | 1.96 Billion INR | 14.42% |
| 2022 Q4 | 523.5 Million INR | 14.58% |
| 2021 Q4 | 359.5 Million INR | -21.47% |
| 2021 FY | 1.71 Billion INR | -3.28% |
| 2021 Q1 | 422.43 Million INR | 40.63% |
| 2021 Q2 | 478.65 Million INR | 13.31% |
| 2021 Q3 | 457.77 Million INR | -4.36% |
| 2020 Q3 | 437.01 Million INR | -7.86% |
| 2020 FY | 1.77 Billion INR | 24.3% |
| 2020 Q2 | 474.31 Million INR | -16.49% |
| 2020 Q4 | 300.37 Million INR | -31.27% |
| 2020 Q1 | 567.95 Million INR | 75.75% |
| 2019 FY | 1.42 Billion INR | 13.05% |
| 2019 Q2 | 366.48 Million INR | 6.1% |
| 2019 Q3 | 394.33 Million INR | 7.6% |
| 2019 Q4 | 323.15 Million INR | -18.05% |
| 2019 Q1 | 345.4 Million INR | 34.49% |
| 2018 FY | 1.26 Billion INR | -15.57% |
| 2018 Q4 | 256.82 Million INR | -29.03% |
| 2018 Q3 | 361.87 Million INR | 7.82% |
| 2018 Q1 | 310.08 Million INR | 0.0% |
| 2018 Q2 | 335.62 Million INR | 8.24% |
| 2017 FY | 1.49 Billion INR | 21.44% |
| 2016 Q4 | 287.53 Million INR | 0.0% |
| 2016 FY | 1.23 Billion INR | -4.08% |
| 2015 FY | 1.28 Billion INR | -10.1% |
| 2014 FY | 1.42 Billion INR | 7.2% |
| 2013 Q4 | 378.89 Million INR | 6.39% |
| 2013 Q1 | 296.03 Million INR | -3.84% |
| 2013 Q3 | 356.14 Million INR | 0.0% |
| 2013 FY | 1.33 Billion INR | 19.55% |
| 2012 FY | 1.11 Billion INR | 5.67% |
| 2012 Q3 | 257.96 Million INR | -5.52% |
| 2012 Q4 | 307.84 Million INR | 19.34% |
| 2012 Q2 | 273.02 Million INR | -1.42% |
| 2012 Q1 | 276.95 Million INR | 0.0% |
| 2011 FY | 1.05 Billion INR | 35.81% |
| 2010 FY | 777.45 Million INR | 26.16% |
| 2009 FY | 616.24 Million INR | 41.78% |
| 2008 FY | 434.65 Million INR | 34.8% |
| 2007 FY | 322.44 Million INR | 58.48% |
| 2006 FY | 203.46 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 87.925% |
| Hester Biosciences Limited | 908.84 Million INR | -110.849% |
| Aarti Drugs Limited | 1.16 Billion INR | -64.139% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 37.67% |
| Albert David Limited | 1.02 Billion INR | -86.746% |
| Alembic Limited | 872.45 Million INR | -119.642% |
| Alkem Laboratories Limited | 32.83 Billion INR | 94.164% |
| Bafna Pharmaceuticals Limited | 455.58 Million INR | -320.621% |
| Bajaj HealthCare Limited | 985.34 Million INR | -94.478% |
| Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -27998.006% |
| Brooks Laboratories Limited | 51.18 Million INR | -3644.205% |
| Eris Lifesciences Limited | 4.94 Billion INR | 61.232% |
| FDC Limited | 3.49 Billion INR | 45.245% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 83.538% |
| Gufic Biosciences Limited | 1.18 Billion INR | -61.495% |
| Hikal Limited | 4.46 Billion INR | 57.071% |
| Ind-Swift Limited | 946.56 Million INR | -102.446% |
| Innova Captab Limited | 931.03 Million INR | -105.824% |
| IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 12.936% |
| Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | -336.959% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 86.742% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -78.394% |
| Lupin Limited | 125.09 Billion INR | 98.468% |
| Mangalam Drugs & Organics Limited | 162.22 Million INR | -1081.229% |
| Medico Remedies Limited | 59.67 Million INR | -3111.201% |
| Morepen Laboratories Limited | 1.98 Billion INR | 3.581% |
| Nectar Lifesciences Limited | 932.7 Million INR | -105.456% |
| Orchid Pharma Limited | 800.77 Million INR | -139.305% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 36.026% |
| RPG Life Sciences Limited | 1.63 Billion INR | -17.168% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -364.636% |
| Sigachi Industries Limited | 579.88 Million INR | -230.458% |
| Solara Active Pharma Sciences Limited | 2.55 Billion INR | 24.972% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -36.605% |
| Themis Medicare Limited | 1.12 Billion INR | -70.216% |
| Unichem Laboratories Limited | 6.72 Billion INR | 71.509% |
| Vaishali Pharma Limited | 84.02 Million INR | -2180.503% |
| Wanbury Limited | 978.96 Million INR | -95.746% |
| Windlas Biotech Limited | 1 Billion INR | -90.389% |
| ZIM Laboratories Limited | 1.01 Billion INR | -89.158% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | 9.787% |
| Ipca Laboratories Limited | 18.98 Billion INR | 89.908% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 98.757% |
| Sakar Healthcare Limited | 204.07 Million INR | -838.991% |
| Aurobindo Pharma Limited | 55.65 Billion INR | 96.557% |
| Divi's Laboratories Limited | 14.17 Billion INR | 86.476% |
| AstraZeneca Pharma India Limited | 2.47 Billion INR | 22.527% |
| Mankind Pharma Limited | 29.27 Billion INR | 93.454% |
| Sequent Scientific Limited | 2.9 Billion INR | 33.962% |
| Laurus Labs Limited | 11.9 Billion INR | 83.91% |
| Neuland Laboratories Limited | 2.92 Billion INR | 34.592% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 87.046% |
| Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 95.919% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 98.47% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | 8.489% |
| Wockhardt Limited | 8.48 Billion INR | 77.402% |
| Bal Pharma Limited | 555.62 Million INR | -244.887% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 98.001% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -35.024% |
| Par Drugs and Chemicals Limited | 58.28 Million INR | -3187.612% |
| Caplin Point Laboratories Limited | 2.17 Billion INR | 11.875% |
| Shilpa Medicare Limited | 3.33 Billion INR | 42.526% |
| Valiant Laboratories Limited | 138.02 Million INR | -1288.32% |
| Ajanta Pharma Limited | 30.46 Billion INR | 93.709% |
| Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -13382.615% |
| Granules India Limited | 10.31 Billion INR | 81.418% |
| Medicamen Biotech Limited | 335.16 Million INR | -471.74% |
| Syncom Formulations (India) Limited | 345.63 Million INR | -454.427% |
| Piramal Enterprises Limited | 63.65 Billion INR | 96.989% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 91.055% |
| NATCO Pharma Limited | 10.05 Billion INR | 80.948% |
| Suven Life Sciences Limited | 109.75 Million INR | -1646.045% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -4051.755% |
| Strides Pharma Science Limited | 9.16 Billion INR | 79.085% |
| Indoco Remedies Limited | 12.06 Billion INR | 84.112% |
| Alpa Laboratories Limited | 127.38 Million INR | -1404.384% |
| Lasa Supergenerics Limited | 291.17 Million INR | -558.123% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 37.718% |